Accuvest Global Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Accuvest Global Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,421	Closed	-$1.99M	–	141
2023 Q1	$1.99M	Buy	2,421 +1,699	+235%	+$1.28M	0.9%	24
2022 Q4	$521K	Buy	722 +400	+124%	+$295K	0.17%	89
2022 Q3	$222K	Sell	322 -306	-49%	-$193K	0.15%	93
2022 Q2	$371K	Sell	628 -48	-7%	-$31.2K	0.24%	72
2022 Q1	$472K	Buy	676 +182	+37%	+$115K	0.24%	71
2021 Q4	$312K	Buy	494 +22	+5%	+$13.5K	0.14%	96
2021 Q3	$286K	Buy	+472	New	+$293K	0.14%	102

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Accuvest Global Advisors's REGN Position: Q2 2023 in Review

Accuvest Global Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 2,421 shares — an estimated $1.99M sold.

Accuvest Global Advisors first reported a position in REGN in Q3 2021 and held it in 7 quarters. The position peaked at $1.99M in Q1 2023. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Accuvest Global Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Accuvest Global Advisors sold 2,421 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $1.99M.
Accuvest Global Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Accuvest Global Advisors's Regeneron Pharmaceuticals position peaked at $1.99M in Q1 2023.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Accuvest Global Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.